Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage For use as a female contraceptive (depot).
Marketing Status Prescription; Discontinued
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 65089-0053; 64918-1500; 60870-0475; 78206-145; 71161-147; 63190-0480; 63190-0260; 45541-1192; 64918-1906
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.080428%
Drug hypersensitivity10.01.01.001--Not Available
Dry skin23.03.03.001--
Dysfunctional uterine bleeding05.05.01.003; 21.01.01.0010.007012%Not Available
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.0020.044545%
Dyspareunia19.08.05.004; 21.03.02.0160.002475%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea02.01.03.002; 22.02.01.004--
Dysuria20.02.02.002--
Eating disorder14.03.01.008; 19.09.01.008--Not Available
Ectopic pregnancy18.02.02.0020.007837%Not Available
Eczema23.03.04.0060.003300%
Emotional disorder19.04.02.0050.016086%Not Available
Endometriosis21.07.01.0040.002475%Not Available
Endometritis11.01.10.005; 21.14.01.0020.001237%Not Available
Epilepsy17.12.03.002--Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.0010.020623%Not Available
Erythema nodosum10.02.01.020; 23.07.02.0010.000825%Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Facial pain08.01.08.0120.001650%
Fat tissue increased08.01.03.0090.002062%Not Available
Fatigue08.01.01.002--
Fear19.06.03.001--Not Available
Feeling abnormal08.01.09.0140.031759%Not Available
Feeling cold08.01.09.008--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages